Established and novel disease-modifying treatments in multiple sclerosis
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Established and novel disease-modifying treatments in multiple sclerosis
Authors
Keywords
-
Journal
JOURNAL OF INTERNAL MEDICINE
Volume 275, Issue 4, Pages 350-363
Publisher
Wiley
Online
2014-01-20
DOI
10.1111/joim.12203
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
- (2013) Omar Khan et al. ANNALS OF NEUROLOGY
- Blocking LINGO-1 as a Therapy to Promote CNS Repair: From Concept to the Clinic
- (2013) Sha Mi et al. CNS DRUGS
- The road to remyelination in demyelinating diseases: current status and prospects for clinical treatment
- (2013) Bharath Wootla et al. Expert Review of Clinical Immunology
- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
- (2013) Ralf Gold et al. LANCET
- New and emerging disease modifying therapies for multiple sclerosis
- (2012) Shiv Saidha et al. Annals of the New York Academy of Sciences
- Dimethyl fumarate - only an anti-psoriatic medication?
- (2012) Markus Meissner et al. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study
- (2012) Peter Connick et al. LANCET NEUROLOGY
- Alemtuzumab more effective than interferon -1a at 5-year follow-up of CAMMS223 Clinical Trial
- (2012) A. J. Coles et al. NEUROLOGY
- Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
- (2012) Giancarlo Comi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome
- (2012) R. Deogracias et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Modulation of Autoimmune Demyelination by Laquinimod via Induction of Brain-Derived Neurotrophic Factor
- (2011) Jan Thöne et al. AMERICAN JOURNAL OF PATHOLOGY
- Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway
- (2011) Ralf A. Linker et al. BRAIN
- Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
- (2011) Grant A Hill-Cawthorne et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Insight into the mechanism of laquinimod action
- (2011) W. Brück et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
- (2011) Ludwig Kappos et al. LANCET
- Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study
- (2011) Bhupendra Khatri et al. LANCET NEUROLOGY
- Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases
- (2011) Antonio Uccelli et al. LANCET NEUROLOGY
- Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study
- (2011) Ludwig Kappos et al. Multiple Sclerosis Journal
- Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone
- (2011) V. Martinelli et al. NEUROLOGY
- Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
- (2011) M. Cossburn et al. NEUROLOGY
- Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
- (2011) P. W. O'Connor et al. NEUROLOGY
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-JC virus antibodies: Implications for PML Risk Stratification
- (2010) Leonid Gorelik et al. ANNALS OF NEUROLOGY
- Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: A pilot study
- (2010) Bassem Yamout et al. JOURNAL OF NEUROIMMUNOLOGY
- Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
- (2010) Daniel Wynn et al. LANCET NEUROLOGY
- The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group
- (2010) Mark S Freedman et al. Multiple Sclerosis Journal
- Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
- (2010) Volker Brinkmann et al. NATURE REVIEWS DRUG DISCOVERY
- Fingolimod is a potential novel therapy for multiple sclerosis
- (2010) Orhan Aktas et al. Nature Reviews Neurology
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis
- (2009) Bibiana Bielekova et al. ARCHIVES OF NEUROLOGY
- FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system
- (2009) Volker Brinkmann BRITISH JOURNAL OF PHARMACOLOGY
- Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model
- (2009) Yanping Hu et al. IMMUNOLOGY
- Monoclonal antibodies in MS: Mechanisms of action
- (2009) B. Bielekova et al. NEUROLOGY
- Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
- (2009) B. O. Khatri et al. NEUROLOGY
- Remyelination protects axons from demyelination-associated axon degeneration
- (2008) K. A. Irvine et al. BRAIN
- Autologous haematopoietic stem-cell transplantation in multiple sclerosis
- (2008) Gianluigi Mancardi et al. LANCET NEUROLOGY
- Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients
- (2007) E. Le Page et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started